PATCHNCT07920081
Psilocybin for Amblyopia - Targeting Critical Periods in Humans
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Change in Amblyopic Eye Visual Acuity
Timeframe: from Baseline to two weeks after experimental drug session 2
Change in Fellow Eye Visual Acuity
Timeframe: from Baseline to two weeks after experimental drug session 2
Secondary (5)
Challenging Experiences Questionnaire (CEQ)
11-Dimensional Altered States of Consciousness Questionnaire (11D-ASC)
The World Health Organization-Five Well-Being Index (WHO-5)
Amblyopia and Strabismus Questionnaire: English (ASQE)
Sheehan Disability Scale (SDS)
Arms and interventions
1 mg Psilocybin with Amblyopia TherapyExperimental
5 mg Psilocybin with Amblyopia TherapyExperimental
10 mg Psilocybin with Amblyopia TherapyExperimental
15 mg Psilocybin with Amblyopia TherapyExperimental
20 mg Psilocybin with Amblyopia TherapyExperimental
25 mg Psilocybin with Amblyopia TherapyExperimental
Behavioral: Amblyopia Therapy
Drugs: 1 mg Psilocybin, 5 mg Psilocybin, 10 mg Psilocybin, 15 mg Psilocybin, 20 mg Psilocybin, 25 mg Psilocybin
Sites
1 site in 1 country
- Johns Hopkins Center for Psychedelic and Consciousness ResearchBaltimore, Maryland, United States